Lee's Pharmaceutical Holdings (STU:L1PA) 5-Year EBITDA Growth Rate : -6.70% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lee's Pharmaceutical Holdings 5-Year EBITDA Growth Rate?

Lee's Pharmaceutical Holdings's EBITDA per Share for the six months ended in Dec. 2024 was €0.01.

During the past 12 months, Lee's Pharmaceutical Holdings's average EBITDA Per Share Growth Rate was 35.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -50.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -6.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lee's Pharmaceutical Holdings was 244.80% per year. The lowest was -50.30% per year. And the median was 20.00% per year.

Competitive Comparison of Lee's Pharmaceutical Holdings's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lee's Pharmaceutical Holdings's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Lee's Pharmaceutical Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Lee's Pharmaceutical Holdings (STU:L1PA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Lee's Pharmaceutical Holdings 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

00950:Hong Kong

Address

Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG

Website

https://www.leespharm.com

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines